Clinical Trials | October 30, 2023
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Lupin enters into BTA with Lupin Manufacturing Solutions
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Subscribe To Our Newsletter & Stay Updated
